Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYAD NASDAQ:IDYA OTCMKTS:NWPHF NASDAQ:PHAS NASDAQ:SRRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsIDYAIDEAYA Biosciences$22.48-1.4%$20.54$13.45▼$44.42$1.97B0.03993,697 shs804,315 shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$37.49M0.53600 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsSRRASierra Oncology$54.99$54.93$14.91▼$55.19$1.34B0.03931,731 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences0.00%+1.77%+0.90%+34.21%-39.76%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%-22.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+6,910.00%SRRASierra Oncology0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyadN/AN/AN/AN/AN/AN/AN/AN/AIDYAIDEAYA Biosciences3.6084 of 5 stars3.41.00.04.42.11.70.0NWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASRRASierra OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.85Moderate Buy$47.55111.50% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ASRRASierra Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYAD, SRRA, PHAS, IDYA, and NWPHF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025IDYAIDEAYA BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$25.007/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad$200K79.56N/AN/A$0.02 per share30.00IDYAIDEAYA Biosciences$7M281.26N/AN/A$12.25 per share1.84NWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SRRASierra Oncology$300K4,476.00N/AN/A$6.16 per share8.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AIDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASRRASierra Oncology-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/ALatest CYAD, SRRA, PHAS, IDYA, and NWPHF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85N/AN/AN/A$3.48 millionN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyadN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASRRASierra OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad1.492.292.14IDYAIDEAYA BiosciencesN/A13.9213.92NWPHFNewron PharmaceuticalsN/AN/AN/APHASPhaseBio PharmaceuticalsN/A0.470.47SRRASierra Oncology0.0221.2721.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyadN/AIDYAIDEAYA Biosciences98.29%NWPHFNewron PharmaceuticalsN/APHASPhaseBio Pharmaceuticals49.02%SRRASierra Oncology99.30%Insider OwnershipCompanyInsider OwnershipCYADCelyad0.94%IDYAIDEAYA Biosciences2.50%NWPHFNewron PharmaceuticalsN/APHASPhaseBio Pharmaceuticals9.90%SRRASierra Oncology44.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad9526.52 million26.28 millionNot OptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSRRASierra Oncology10924.42 million13.65 millionOptionableCYAD, SRRA, PHAS, IDYA, and NWPHF HeadlinesRecent News About These CompaniesGSK bolsters cancer pipeline with $1.9bn Sierra Oncology buyOctober 4, 2024 | pharmaphorum.comPNew cancer treatment center breaks ground in ReddingSeptember 25, 2024 | actionnewsnow.comAImplementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community HospitalSeptember 19, 2024 | ascopubs.orgANew regional cancer center in Redding is called the Sierra Pacific Regional Cancer CenterAugust 21, 2024 | actionnewsnow.comASierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Space, valued at $5.3 billion, eyes IPO to 'accelerate the new space economy'April 11, 2024 | aol.comAUsed 2021 GMC Sierra 2500 trucks for sale near meApril 5, 2024 | cars.comCAnemia of InflammationMarch 26, 2024 | nejm.orgNSierra Oncology Inc.February 21, 2024 | thestreet.comSierra Leone Airport, Sierra Leone, Sierra Leone [ SRK / ]February 15, 2024 | prokerala.comP2014 GMC Sierra 1500 specs & colorsFebruary 6, 2024 | cars.comCUsed 2014 GMC Sierra 1500 Denali trucks for sale near meJanuary 5, 2024 | cars.comC2017 GMC Sierra 1500December 17, 2023 | motortrend.comMSafety in Radiation Oncology (SAFRON)December 16, 2023 | iaea.orgI2024 GMC Sierra 2500HDNovember 24, 2023 | driving.caDSierra deputies believe bear mauled woman after she diedNovember 20, 2023 | kcra.comKSierra Coupon for OctoberNovember 9, 2023 | time.comTCompare 6 trims on the 2021 GMC Sierra 1500October 31, 2023 | cars.comCClario presents a three-part webinar series on oncology trial solutionsOctober 31, 2023 | galvnews.comGFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeLululemon, UNH, Enphase: Bad News, Good Opportunity?By Thomas Hughes | June 17, 2025View Lululemon, UNH, Enphase: Bad News, Good Opportunity?Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?Super Micro’s Bold $2B Bond Plan Signals 35% Premium UpsideBy Gabriel Osorio-Mazilli | June 26, 2025View Super Micro’s Bold $2B Bond Plan Signals 35% Premium UpsideCYAD, SRRA, PHAS, IDYA, and NWPHF Company DescriptionsCelyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.IDEAYA Biosciences NASDAQ:IDYA$22.48 -0.32 (-1.40%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$22.46 -0.02 (-0.09%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 07/11/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Sierra Oncology NASDAQ:SRRASierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
